Inozyme Pharma (NASDAQ:INZY) Stock Rating Reaffirmed by Wedbush

Inozyme Pharma (NASDAQ:INZY – Get Rating)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research report issued to clients and investors on Tuesday, RTT News reports. They presently have a $23.00 target price on the stock, down from their prior target price of $25.00. Wedbush’s price objective would indicate a […]

Related Keywords

New York ,United States ,Inozyme Pharma ,Axel Bolte ,Robert Lorne Hopfner ,Morgan Stanley ,York State Common Retirement Fund ,Geode Capital Management ,Russell Investments Group Ltd ,Inozyme Pharma Inc ,Zacks Investment Research ,Needham Company ,Sg Americas Securities ,Get Rating ,Director Robert Lorne Hopfner ,Investments Group ,Capital Management ,Nasdaq Inzy ,Minzy ,Medical ,Reiterated Rating ,Wedbush ,